Payment overview · 2025
General Payments
$1,616.98
24 reported records · 13 companies
Healthcare provider profile · identity verified
Timothy Eng
Allopathic & Osteopathic Physicians|Internal Medicine · BROOKLYN, NY · NPI 1730685231
Verified facts
What the public records show
CMS Open Payments records show Timothy Eng received $1,616.98 in general payments during 2025 across 24 reported records.
Madrigal Pharmaceuticals accounted for 25.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Creon, Linzess, Prolia, Trelegy Ellipta, Vemlidy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 94 claims for Linzess by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NEXIUM as an associated drug or biological on 464 records involving 299 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Nexium by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Vemlidy as an associated drug or biological on 782 records involving 554 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Vemlidy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Trelegy Ellipta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $407.11 | 25.2% | 3 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $264.10 | 16.3% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $185.92 | 11.5% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $150.00 | 9.3% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $150.00 | 9.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $125.00 | 7.7% | 1 | 2025 |
| Agios Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $124.97 | 7.7% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $72.31 | 4.5% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $40.33 | 2.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $39.84 | 2.5% | 2 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $24.10 | 1.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $17.97 | 1.1% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.33 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,616.98 | 24 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $407.11 | 3 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $168.68 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $150.00 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| Vemlidy Normalized: vemlidy |
Drug | Gilead Sciences, Inc. | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| PYRUKYND Normalized: pyrukynd |
Drug | Agios Pharmaceuticals, Inc. | $124.97 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $72.31 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $40.33 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $39.84 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $35.92 | 2 | 2025 |
Source payment records
|
|||||
| APRETUDE Normalized: apretude |
Drug | ViiV Healthcare Company | $24.10 | 1 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $18.07 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $17.97 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $15.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CREON creon |
2025 | Creon | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 94 | exact normalized | Medicare Part D |
| PROLIA prolia |
2025 | Prolia | 2024 | 24 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 86 | exact normalized | Medicare Part D |
| Vemlidy vemlidy |
2025 | Vemlidy | 2024 | 80 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
94 | 51 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
24 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
66 | 24 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | NEXIUM open payments reported associated product |
CMS Open Payments — General Payments 464 supporting records · 299 recipient NPIs · example record 1206134180 |
Nexium · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Vemlidy open payments reported associated product |
CMS Open Payments — General Payments 782 supporting records · 554 recipient NPIs · example record 1234350906 |
Vemlidy · 2024 Exact normalized brand match · 1 Part D row |
80 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
34 | 34 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
22 | 17 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
86 | 31 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
60 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 872 | 310 |
| Gabapentin | Gabapentin | 459 | 185 |
| Donepezil Hcl | Donepezil Hcl | 437 | 159 |
| Amlodipine Besylate | Amlodipine Besylate | 425 | 157 |
| Losartan Potassium | Losartan Potassium | 394 | 158 |
| Diclofenac Epolamine | Diclofenac Epolamine | 362 | 103 |
| Metoprolol Succinate | Metoprolol Succinate | 308 | 96 |
| Diclofenac Sodium | Diclofenac Sodium | 288 | 172 |
| Tamsulosin Hcl | Tamsulosin Hcl | 288 | 117 |
| Vascepa | Icosapent Ethyl | 264 | 78 |
| Fluticasone Propionate | Fluticasone Propionate | 214 | 105 |
| Metformin Hcl | Metformin Hcl | 209 | 79 |
| Jardiance | Empagliflozin | 204 | 63 |
| Famotidine | Famotidine | 194 | 125 |
| Ammonium Lactate | Ammonium Lactate | 191 | 123 |
| Finasteride | Finasteride | 164 | 68 |
| Simvastatin | Simvastatin | 164 | 47 |
| Omeprazole | Omeprazole | 161 | 106 |
| Azithromycin | Azithromycin | 131 | 112 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 128 | 47 |
| Alendronate Sodium | Alendronate Sodium | 121 | 55 |
| Mirtazapine | Mirtazapine | 118 | 58 |
| Raloxifene Hcl | Raloxifene Hcl | 118 | 41 |
| Montelukast Sodium | Montelukast Sodium | 113 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 107 | 28 |
| Trazodone Hcl | Trazodone Hcl | 107 | 61 |
| Meclizine Hcl | Meclizine Hcl | 97 | 67 |
| Linzess | Linaclotide | 94 | 51 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 93 | 44 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 86 | 31 |
| Vemlidy | Tenofovir Alafenamide | 80 | 12 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 77 | 24 |
| Meloxicam | Meloxicam | 73 | 49 |
| Naproxen | Naproxen | 68 | 52 |
| Farxiga | Dapagliflozin Propanediol | 66 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 65 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 65 | 24 |
| Mupirocin | Mupirocin | 63 | 38 |
| Allopurinol | Allopurinol | 60 | 24 |
| Eliquis | Apixaban | 60 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 60 | 20 |
| Glipizide Er | Glipizide | 59 | 24 |
| Hydrocortisone | Hydrocortisone | 59 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 58 | 45 |
| Pioglitazone Hcl | Pioglitazone Hcl | 54 | 20 |
| Carvedilol | Carvedilol | 52 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 50 | 32 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 49 | 27 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 47 | 31 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | 29 |
| Loperamide | Loperamide Hcl | 44 | 36 |
| Xarelto | Rivaroxaban | 44 | 17 |
| Ezetimibe | Ezetimibe | 42 | 13 |
| Januvia | Sitagliptin Phosphate | 42 | 15 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 41 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 41 | 26 |
| Lisinopril | Lisinopril | 40 | 15 |
| Metronidazole | Metronidazole | 37 | 30 |
| Trulicity | Dulaglutide | 37 | suppressed |
| Atenolol | Atenolol | 36 | suppressed |
| Bepotastine Besilate | Bepotastine Besilate | 36 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 36 | 29 |
| Pravastatin Sodium | Pravastatin Sodium | 36 | 12 |
| Tenofovir Disoproxil Fumarate | Tenofovir Disoproxil Fumarate | 36 | suppressed |
| Rybelsus | Semaglutide | 35 | 14 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 34 | 34 |
| Valsartan | Valsartan | 34 | 12 |
| Clonazepam | Clonazepam | 32 | 16 |
| Tradjenta | Linagliptin | 32 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 31 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 30 | 14 |
| Ibuprofen | Ibuprofen | 30 | 23 |
| Methimazole | Methimazole | 30 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 22 |
| Glimepiride | Glimepiride | 25 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 25 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 25 | suppressed |
| Colchicine | Colchicine | 24 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 24 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 24 | 12 |
| Metformin Hcl Er | Metformin Hcl | 24 | 11 |
| Prolia | Denosumab | 24 | 19 |
| Zolpidem Tartrate | Zolpidem Tartrate | 24 | 14 |
| Celecoxib | Celecoxib | 23 | 17 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 22 | 17 |
| Levofloxacin | Levofloxacin | 21 | 17 |
| Fenofibrate | Fenofibrate,micronized | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 19 | 11 |
| Jentadueto | Linagliptin/Metformin Hcl | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 19 | suppressed |
| Creon | Lipase/Protease/Amylase | 18 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Nexium | Esomeprazole Magnesium | 17 | suppressed |
| Restasis | Cyclosporine | 17 | suppressed |
| Telmisartan | Telmisartan | 17 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 16 | 15 |
| Ozempic | Semaglutide | 16 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 16 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Ciclopirox | Ciclopirox | 15 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 15 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 14 | suppressed |
| Furosemide | Furosemide | 14 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 13 | suppressed |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 12 | suppressed |
| Entresto | Sacubitril/Valsartan | 12 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 12 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Metformin Er Gastric | Metformin Hcl | 12 | suppressed |
| Procto-Med Hc | Hydrocortisone | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 11 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Pregabalin | Pregabalin | 11 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,616.98 · 24 records | Madrigal Pharmaceuticals | AIRSUPRA, APRETUDE, Auvelity, CREON, Cologuard Collection Kit, EVENITY, LINZESS, PAXLOVID, PROLIA, PYRUKYND, REXULTI, REZDIFFRA, TRELEGY ELLIPTA, VOQUEZNA, Vemlidy | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Creon play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error